|
||
Tranexamic Acid Pregnancy |
||
Tranexamic Acid crosses the placenta; concentrations within cord blood are similar to maternal serum.
Use of oral Tranexamic Acid for the long-term prophylaxis of HAE in pregnant females has been reported (González-Quevedo 2016; Machado 2017; Milingos 2009). Tranexamic Acid may be considered for long-term prophylaxis when preferred treatment is not available (WAO/EEACI [Maurer 2018]).
Intravenous Tranexamic Acid has been evaluated for the treatment of postpartum hemorrhage (Ducloy-Bouthors 2011; WOMAN Trial Collaborators 2017). A significant reduction in risk of death due to bleeding was observed when treatment was started within 3 hours of vaginal birth or cesarean section (WOMAN Trial Collaborators 2017). Tranexamic Acid is recommended for the treatment of obstetric hemorrhage when initial therapy fails (ACOG 183 2017; WHO 2017). IV Tranexamic Acid has also been studied for prophylaxis of postpartum hemorrhage in low-risk females prior to vaginal or cesarean delivery (Novikova 2015; Sentilhes 2018; Simonazzi 2016). However, available data related to prophylactic use is insufficient and use for routine prophylaxis against postpartum hemorrhage is not currently recommended outside of the context of clinical research (ACOG 183 2017).
Tranexamic Acid should be used during lactation only if clearly needed. Excreted into human milk: Yes Excreted into animal milk: Data not available The effects in the nursing infant are unknown.
Tranexamic Acid is excreted into human milk at a concentration of about one hundredth of the corresponding serum concentrations.
See references
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
|